· ISIN: GB00BZ4G2K23

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 12.08.2025 | 11:35
12 August 2025 11:35AM
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
GB00BZ4G2K23
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025...
© Globe Newswire
13 May 2025 11:30AM
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
GB00BZ4G2K23
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI)...
© Globe Newswire
26 March 2025 11:30AM
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
GB00BZ4G2K23
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025...
© Globe Newswire
12 January 2025 04:05PM
Mereo BioPharma Provides Update on Lead Clinical Programs
GB00BZ4G2K23
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025...
© Globe Newswire
12 September 2024 09:35PM
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
GB00BZ4G2K23
LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on Wednesday...
© Globe Newswire
13 August 2024 12:00PM
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GB00BZ4G2K23
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled...
© Globe Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.